Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) – Pipeline Review, H2 2016’, provides in depth analysis on Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)

The report reviews Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Amgen Inc.

Millennium Pharmaceuticals Inc

ProNAi Therapeutics, Inc.

SBI Biotech Co., Ltd.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC

2.7.11.1) Overview 6

Therapeutics Development 7

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC

2.7.11.1) - Products under Development by Stage of Development 7

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC

2.7.11.1) - Products under Development by Therapy Area 8

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC

2.7.11.1) - Products under Development by Indication 9

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC

2.7.11.1) - Pipeline Products Glance 10

Early Stage Products 10

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC

2.7.11.1) - Products under Development by Companies 11

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC

2.7.11.1) - Products under Development by Universities/Institutes 13

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC

2.7.11.1) - Therapeutics Assessment 15

Assessment by Monotherapy/Combination Products 15

Assessment by Mechanism of Action 16

Assessment by Route of Administration 17

Assessment by Molecule Type 18

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC

2.7.11.1) - Companies Involved in Therapeutics Development 19

Amgen Inc. 19

Millennium Pharmaceuticals Inc 20

ProNAi Therapeutics, Inc. 21

SBI Biotech Co., Ltd. 22

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC

2.7.11.1) - Drug Profiles 23

MSK-777 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

PNT-141 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

Small Molecule to Inhibit Cdc7/ASK for Oncology - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

Small Molecules to Inhibit CDC-7 for Pancreatic Cancer - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

Small Molecules to Inhibit CDC7 for Oncology - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

TAK-931 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC

2.7.11.1) - Dormant Projects 29

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC

2.7.11.1) - Discontinued Products 30

Appendix 31

Methodology 31

Coverage 31

Secondary Research 31

Primary Research 31

Expert Panel Validation 31

Contact Us 31

Disclaimer 32

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Products under Development by Companies, H2 2016 12

Number of Products under Investigation by Universities/Institutes, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Stage and Mechanism of Action, H2 2016 16

Number of Products by Stage and Route of Administration, H2 2016 17

Number of Products by Stage and Molecule Type, H2 2016 18

Pipeline by Amgen Inc., H2 2016 19

Pipeline by Millennium Pharmaceuticals Inc, H2 2016 20

Pipeline by ProNAi Therapeutics, Inc., H2 2016 21

Pipeline by SBI Biotech Co., Ltd., H2 2016 22

Dormant Projects, H2 2016 29

Discontinued Products, H2 2016 30

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 10

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Stage and Mechanism of Actions, H2 2016 16

Number of Products by Stage and Routes of Administration, H2 2016 17

Number of Products by Stage and Molecule Type, H2 2016 18

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports